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Aims: The aim of the present study was to investigate the impact of aspirin on prognosis in 2 
takotsubo syndrome (TTS).  3 
Methods and Results: Patients from the International Takotsubo Registry (InterTAK Registry) 4 
were categorized into two groups based on aspirin prescription at discharge. A comparison of 5 
clinical outcomes between the two groups was performed using an adjusted analysis with 6 
propensity score stratification; results from the unadjusted analysis were also reported to note the 7 
effect of the PS adjustment. Major adverse cardiac and cerebrovascular events (MACCE: a 8 
composite of death, myocardial infarction, TTS recurrence, stroke or transient ischemic attack 9 
[TIA]) were assessed at 30-day and 5-year follow-up. A total of 1533 TTS patients with known 10 
status regarding aspirin prescription at discharge were included. According to the adjusted analysis 11 
based on PS stratification, aspirin was not associated with a lower hazard of MACCE at 30-day 12 
(Hazard ratio [HR] 1.24, 95% confidence interval [CI] 0.50-3.04, P=0.64) or 5-year follow-up (HR 13 
1.11, 95% CI 0.78-1.58, P=0.58). These results were confirmed by sensitivity analyses performed 14 
with alternative PS based methods, i.e. covariate adjustment and inverse probability of treatment 15 
weighting. 16 
Conclusion: In the present study, no association was found between aspirin use in TTS patients 17 
and a reduced risk of MACCE at 30-day and 5-year follow-up. These findings should be confirmed 18 
in adequately powered randomized controlled trials. (ClinicalTrials.gov number: NCT01947621) 19 
 20




Takotsubo syndrome (TTS) mostly affects postmenopausal women and is usually preceded 2 
by an emotional or physical trigger.1-3 Clinical symptoms and signs at presentation, along with 3 
electrocardiographic (ECG) and laboratory changes, may mimic acute coronary syndrome (ACS) 4 
or acute heart failure.1, 4-6 Although TTS has long been considered a benign condition, recent 5 
studies reported that it can be associated with significant adverse events both during 6 
hospitalization and after discharge.1, 7-12 Therefore, there is a compelling need for an optimal 7 
preventive therapy to reduce the incidence of adverse events following TTS. According to recent 8 
data, angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers have been 9 
reported to reduce mortality1 and recurrence of TTS,13 while beta-blockers have not shown 10 
beneficial effects.1, 14 However, data on therapeutic management of TTS are mainly based on small 11 
case series,15 meta-analyses,13, 16 or retrospective data. There is still a lack of knowledge available 12 
on optimal treatment strategies.  13 
During the acute phase of TTS, a thrombogenic state may arise as a consequence of 14 
catecholamine-dependent ventricular dysfunction, platelet activation, and/or vasoconstriction.17 15 
While anticoagulation therapy in the presence of left ventricular thrombus seems to be an 16 
appropriate choice, a recent retrospective study has also suggested a protective effect of anti-17 
platelet therapy during index TTS hospitalization.18 However, uncertainty persists regarding an 18 
association between aspirin use and adverse events in TTS patients post-discharge. Therefore, 19 
the present study aimed to investigate the impact of aspirin use in a large TTS patient cohort 20 




Data collection 2 
The InterTAK Registry is an observational, prospective, and retrospective registry 3 
established at the University Hospital Zurich in 2011 in collaboration with 25 cardiovascular centers 4 
across 9 countries.1, 3 Patients were included in the registry between 2011 and 2014 based on 5 
modified Mayo Clinic Diagnostic Criteria as previously reported:1, 19 i) transient abnormality of left 6 
ventricular wall-motion extending beyond a single coronary artery perfusion territory, ii) absence of 7 
obstructive coronary artery disease (CAD) or evidence of acute plaque rupture, iii) presence of new 8 
electrocardiographic abnormalities or elevation in troponin and iv) absence of 9 
pheochromocytoma/myocarditis. Exceptions included coexisting CAD in whom the wall motion 10 
abnormality was congruent with a single coronary artery territory or death during the acute phase 11 
before documentation of wall motion recovery. Data on demographics, triggering factors, 12 
cardiovascular risk factors, haemodynamic and angiographic findings, ECG and echocardiography 13 
parameters, laboratory values, use of medications, in-hospital complications, and management 14 
were collected through standardized forms on admission or during revision of clinical charts. 15 
For the purpose of the present analysis, patients were divided into two groups according to 16 
the prescription of aspirin at hospital discharge. Patients with unknown status regarding aspirin at 17 
discharge were excluded from the present study. 18 
 The local ethics committee or institutional review board at each participating site reviewed 19
the study protocol. Most ethics committees waived the need for informed consent due to the partly 20 
retrospective nature of the study. Formal written consent was obtained from patients or their 21 
surrogates at participating centers whose ethics committees or institutional review boards required 22 
informed consent or if patients were included prospectively. 23 
 24
Study outcomes 25 
Follow-up data were collected from clinical visits, medical charts, or telephone interviews as 26 
previously described.1 The incidence of major adverse cardiovascular and cerebrovascular events 27 
(MACCE: a composite of all cause death, TTS recurrence, stroke or transient ischemic attack 28 
6 
 
[TIA], or myocardial infarction [MI]) at 30-day and 5-year follow-up were the co-primary outcomes 1 
in the present analysis. Additionally, single components of MACCE at 5-year follow-up were 2 
analysed. 3 
 4
Statistical analysis 5 
In the unadjusted analysis, continuous variables were summarized as mean ± standard deviation 6 
(SD) or median (1st-3rd quartile), and frequencies of categorical variables are presented as 7 
numbers with percentages. Categorical variables were compared with the Pearson chi-square test, 8 
continuous variables with the Student t-test.  9 
An adjusted analysis based on propensity score (PS) was performed. PS is the probability that 10 
each individual patient is included in the treatment group and is usually estimated via logistic 11 
regression based on the available baseline covariates. PS methods are used to compensate for 12 
the lack of proper statistical design and randomization in observational studies, like the present 13 
one. All variables expected to be associated with the outcomes of interest, or with both 14 
aspirin prescription and outcomes, are listed in SupplementaryTable 1 and were used to 15 
construct the PS model. 16 
The first step of the adjusted analysis was the treatment of missing data, which were present for a 17 
high number of variables (69 covariates out of 136). Assuming that data were missing at random 18 
and considering only the variables with less than 50% of missing data (the other covariates were 19 
excluded from the analyses)20, we used polytomus logistic regression, logistic regression and 20 
predictive mean matching as multiple imputation techniques to fill in missing values, using the R 21 
mice package (version 3.6.0). We imputed five different datasets and the same statistical analyses 22 
were performed on each of them. After that, Rubin’s rule21 was used to get pooled propensity score 23 
adjusted HR estimates and confidence intervals for each endpoint (primary and secondary), 24 
according to each of the three methods described below: stratification,  and covariate adjustment 25 
and inverse probability of treatment weighting (IPTW) as sensitivity analysis. 26 
With the method based on stratification, the total dataset is divided into mutually exclusive groups 27 
(strata), based on quantiles (in our case, tertiles) of the estimated PS; in this way, subjects from 28 
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both arms are stratified in subsets that are defined by specific thresholds in PS.22, 23 Then, all strata 1 
are included in a stratified proportional hazard Cox model to get an estimate of the HR for 2 
treatment, as previously described by Austin.24  3 
In the case of the covariate adjustment method, a Cox model is built with two predictors, given by 4 
the treatment indicator and PS itself.25 An estimate of the treatment effect is then obtained based 5 
on the Cox model.  6 
Finally, the IPTW technique involves assigning to each patient a stabilised weight equal to  7 
(1-p)/(1-PS) if a control, or equal to p/PS if a treated patient,20 where p is the probability of 8 
treatment without any covariate and PS is the value of the PS for that patient. The choice of 9 
stabilised weights allowed us to work with a pseudo-sample (as large as the sum of the weights) 10 
that has approximately the same size as the actual one.26 Then, the weights were included in the 11 
survival analysis to estimate two adjusted Kaplan-Meier curves27 (one for each treatment). The 12 
weights were also used to estimate the parameters of the Cox model, and in particular the HR.28 13 
No association of any continuous predictor and aspirin prescription departed from linearity, 14 
as assessed through the statistical significance of quadratic and cubic terms. 15 
The adjusted statistical analysis was performed using R 3.5.1 and some of its packages29,30, 16 




Study population 2 
Out of 1750 patients in the InterTAK Registry, 1533 with documented status regarding 3 
aspirin at discharge were included in the present analysis (Figure 1). The mean age was 66.4±13.1 4 
years and 1382 (90.2%) were females. 989 (65.8%) patients had hypertension, 221 (14.7%) 5 
diabetes mellitus, and 480 (32.0%) hypercholesterolemia. ST-segment elevation was observed in 6 
606 (43.5%) patients on admission. An emotional trigger was identified in 447 (29.2%) patients and 7 
a physical trigger in 533 (34.8%). Patients’ characteristics of the total study cohort and of TTS 8 
patients with and without aspirin at discharge are summarized in Table 1. Unadjusted outcomes 9 
are reported in Table 2, showing a higher risk of 5 years death for patients in aspirin and no 10 
difference for the other endpoints. 11 
 12
Adjusted comparison using PS with the stratification method 13 
According to PS stratification method, aspirin was not associated with a reduced hazard of 14 
MACCE at 30-day (HR 1.24, 95% CI 0.50-3.04, P=0.64) or 5-year follow-up (HR 1.11, 95% CI 15 
0.78-1.58, P=0.58). Furthermore, no significant differences were observed for the single 16 
components of MACCE, including death (HR 1.36, 95% CI 0.79-2.34, P=0.27), TTS recurrence 17 
(HR 0.53, 95% CI 0.27-1.03 P=0.06), stroke/TIA (HR 1.52, 95% CI 0.65-3.54, P=0.33), or MI (HR 18 
3.28, 95% CI 0.38-28.28, P=0.28) (Table 2). 19 
 20
Sensitivity analysis: PS covariate adjustment and PS IPTW method 21 
PS IPTW and PS covariate adjustment methods did not show any association between 22 
aspirin and a risk reduction for MACCE or its single components (Table 2), except for TTS 23 
recurrence, which shows some weak association. The survival analysis for MACCE and death 24 
based on IPTW results confirmed these findings as reported in Figure 2, which depicts the Kaplan-25 
Meier curves of the two groups crossing each other. 26 
In order to verify that the application of the IPTW method allowed to achieve a gain in 27 
similarity between the active and control groups, we plotted two “mirrored” histograms showing the 28 
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distribution of PS (averaged on 5 imputed datasets) within each treatment group on the true and 1 
the pseudo populations (see Supplementary Figure 2). After the application of the IPTW method, 2 
the distribution of PS between the two groups looks more symmetrical: treated PSs are “shifted” 3 
towards 0, while untreated PSs towards 1. The difference of frequency within each PS interval 4 
between the active and control groups is due to the different sizes of the two groups, 1031 treated 5 




The increased awareness of TTS has resulted in a higher recognition of TTS among 2 
physicians.31 However, there is still a lack of evidence for specific TTS treatments.  3 
The present study found that aspirin at hospital discharge did not relate to short- nor long-4 
term prognosis in a large population of TTS patients. Incidence of MACCE in patients discharged 5 
with aspirin, who were not randomized but were adjusted for a higher burden of comorbidities with 6 
PS methods, was not significantly different compared to patients without aspirin, both at short and 7 
long-term follow-up. Furthermore, single components of MACCE were similar at 5 years. Presence 8 
of CAD at baseline did not affect these results. 9 
TTS pathophysiology is hypothesized to be mediated by an abrupt surge of catecholamines 10 
leading to ventricular dysfunction.32 An increased cardiac sympathetic activity is known to be 11 
associated with unfavourable outcomes in cardiovascular diseases.33-35 Of note, the 12 
catecholaminergic surge may activate platelets and proinflammatory pathways, setting the stage 13 
for the use of antiplatelet agents such as aspirin. The protective effect of aspirin in acute 14 
cardiovascular diseases, however, is mainly related to the reduction of thrombotic events induced 15 
by platelet activation following plaque erosion or rupture. These mechanisms do not appear to play 16 
a significant role in TTS, as it appears that TTS mainly involves the microcirculatory system, thus 17 
this explains the lack of potential benefit associated with aspirin in this syndrome.36  18 
 Aspirin acts both as an antithrombotic as well as an anti-inflammatory agent, suppressing 19
the production of prostaglandins, thromboxane, and decreasing plasma levels of several 20 
inflammatory biomarkers, posing a potential prognostic benefit in TTS. Nevertheless, a negative 21 
interaction has been shown between aspirin (related to dose) and survival benefit of ACE-inhibitors 22 
therapy in patients admitted for heart failure and could have implications in TTS patients as well.37 23 
In a recent study of Dias et al. a beneficial effect of aspirin on an in-hospital combined endpoint 24 
has been reported when given on TTS index event.18 However, this effect may result from the 25 
combined therapy of aspirin and clopidogrel together. Moreover, the authors evaluated only 26 
hospital events in a relatively low sample size, which may have produced incidental findings. 27 
11 
 
In line with our results, Fazio et al. demonstrated a lack of benefit of in-hospital aspirin 1 
administration on both hospitalisation length and ejection fraction improvement in a relatively small 2 
number of TTS patients.38 Of note, we focused on aspirin use after hospital discharge, also 3 
adjusting for major confounding factors with PS-stratified analysis, and similarly we could not 4 
demonstrate an association between aspirin and improved outcome at follow-up. We found some 5 
evidence of weak association between aspirin and only TTS recurrence; such weak association is 6 
detected by the covariate adjustment and the IPTW methods and not by the stratification method. 7 
Therefore, this potential association should be interpreted carefully, considering the lack of a 8 
supporting pathophysiological mechanism. Since any potential benefit should be pondered with the 9 
inevitable higher bleeding risk in patients taking aspirin on a long-term basis, the routine use of 10 
aspirin should not be encouraged especially in patients at high risk for bleeding.39 11 
Our results suggest that TTS per se does not represent an indication for treatment with 12 
aspirin. Aspirin treatment might be withdrawn even during hospitalisation once the clinical picture 13 
of TTS has been unmasked, unless there are coexisting comorbidities that confer a high 14 
atherosclerotic risk and require antiplatelet therapy according to current guidelines.  15 
 16
Study limitations 17 
The present study is not a randomized controlled trial, but we tried to address this 18 
shortcoming using PS, which may nonetheless adjust only for recorded variables and not for the 19 
missing ones. Given the low prevalence of TTS it is challenging to obtain robust data on treatment 20 
or to conduct comparative randomized controlled trials. Therefore, the application of PS methods is 21 
currently state of the art in this setting.   22 
A methodological limitation of the study is that we mostly observed the absence of aspirin 23 
effects. As it is well known, absence of evidence is not evidence of absence, and a statistical proof 24 
of the lack of aspirin effect should properly be conducted within an equivalence approach using 25 




Performance of PS was tested by assessing the standardized differences before and after 1 
propensity score using IPTW on the covariates used, with satisfactory results (Supplementary 2 
Table 2): in fact, the computation of standardized differences (SD) demonstrate that even though 3 
some of the SDs increased from the unadjusted to the adjusted population, this led to an overall 4 
decrease in all SDs adjusted with IPTW, so that almost all variables have a SD lower than 0.1 5 
between treatment groups. Regarding non linearity, residuals are symmetrically distributed around 6 
0 and lowess interpolation within each plot do not show any particular non-linear relationships (see 7 
supplementary Figure 1).  Moreover, in the stratification analysis, we used 3 strata, with a potential 8 
higher risk of bias: however, the results are consistent with the other two analyses, confirming the 9 
overall strength of our model.   10 
Proper sample size calculation showed that this study is formally underpowered for main 11 
outcomes, although it should be remembered that the present is the largest available registry on 12 
this topic. This is particularly true for MI, which occurred only for 9 patients leading to large CI after 13 
PS adjustement. 14 
The dose-dependent detrimental interaction of aspirin on ACE-Inhibitors therapy survival 15 
benefit makes the net effect of aspirin alone not completely predictable in TTS patients where both 16 




In the present analysis, we found no evidence, after adjusting for potential confounding 21 
factors, that aspirin at discharge is associated with a reduced risk of MACCE at short- or long-term 22 
follow-up in TTS patients. These findings should be confirmed in adequately powered randomized 23 
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FIGURE LEGENDS 1 
Figure 1. Study design. 2 
MACCE denotes major adverse cardiac and cerebrovascular event; TIA transient ischemic attack, 3 
TTS takotsubo syndrome.  4 
 5
Figure 2. Inverse probability of treatment weighting adjusted Kaplan-Meier Analysis.  6 
Colored bands represent the 95% pointwise confidence bands. 7 
MACCE denotes major adverse cardiac and cerebrovascular event; IPTW, inverse probability of 8 
treatment weighting.  9 
 10
 11
